232 related articles for article (PubMed ID: 33126591)
1. Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC.
Cao J; Zhao W; Zhao C; Liu Q; Li S; Zhang G; Chou CJ; Zhang Y
Molecules; 2020 Oct; 25(21):. PubMed ID: 33126591
[TBL] [Abstract][Full Text] [Related]
2. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel HDAC/CD13 dual inhibitors for the treatment of cancer.
Jia G; Qi K; Hou B; Yue K; Xu T; Jiang Y; Li X
Eur J Med Chem; 2023 Nov; 260():115752. PubMed ID: 37647727
[TBL] [Abstract][Full Text] [Related]
4. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.
Tashima T; Murata H; Kodama H
Bioorg Med Chem; 2014 Jul; 22(14):3720-31. PubMed ID: 24864038
[TBL] [Abstract][Full Text] [Related]
6. LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin.
Gao JJ; Gao ZH; Zhao CR; Yuan Y; Cui SX; Zhang XF; Cheng YN; Xu WF; Tang W; Qu XJ
Invest New Drugs; 2011 Aug; 29(4):574-82. PubMed ID: 20111888
[TBL] [Abstract][Full Text] [Related]
7. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
8. Discovery of pomalidomide-based PROTACs for selective degradation of histone deacetylase 8.
Sun Z; Deng B; Yang Z; Mai R; Huang J; Ma Z; Chen T; Chen J
Eur J Med Chem; 2022 Sep; 239():114544. PubMed ID: 35759908
[TBL] [Abstract][Full Text] [Related]
9. Designing HDAC-PROTACs: lessons learned so far.
Fischer F; Alves Avelar LA; Murray L; Kurz T
Future Med Chem; 2022 Jan; 14(3):143-166. PubMed ID: 34951318
[TBL] [Abstract][Full Text] [Related]
10. LYP3, a new bestatin derivative for aminopeptidase N inhibition.
Luan Y; Ma C; Sui Z; Wang X; Feng J; Liu N; Jing F; Wang Y; Li M; Fang H; Xu W
Med Chem; 2011 Jan; 7(1):32-6. PubMed ID: 21235517
[TBL] [Abstract][Full Text] [Related]
11. An efficient synthesis of SK-658 and its analogs as potent histone deacetylase inhibitors.
Shahidul Islam M; Nurul Islam M; Ashraful Hoque M; Nishino N; Kato T; Kim HJ; Ito A; Yoshida M
Bioorg Chem; 2015 Apr; 59():145-50. PubMed ID: 25797804
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.
Huang WJ; Chen CC; Chao SW; Yu CC; Yang CY; Guh JH; Lin YC; Kuo CI; Yang P; Chang CI
Eur J Med Chem; 2011 Sep; 46(9):4042-9. PubMed ID: 21712146
[TBL] [Abstract][Full Text] [Related]
13. Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity.
Negmeldin AT; Padige G; Bieliauskas AV; Pflum MK
ACS Med Chem Lett; 2017 Mar; 8(3):281-286. PubMed ID: 28337317
[TBL] [Abstract][Full Text] [Related]
14. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands.
Lu Y; Sun D; Xiao D; Shao Y; Su M; Zhou Y; Li J; Zhu S; Lu W
Molecules; 2021 Nov; 26(23):. PubMed ID: 34885822
[TBL] [Abstract][Full Text] [Related]
16. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
18. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH
Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008
[TBL] [Abstract][Full Text] [Related]
19. Protective effects of bestatin in the retina of streptozotocin-induced diabetic mice.
Hossain A; Heron D; Davenport I; Huckaba T; Graves R; Mandal T; Muniruzzaman S; Wang S; Bhattacharjee PS
Exp Eye Res; 2016 Aug; 149():100-106. PubMed ID: 27344955
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Huang WJ; Chen CC; Chao SW; Lee SS; Hsu FL; Lu YL; Hung MF; Chang CI
ChemMedChem; 2010 Apr; 5(4):598-607. PubMed ID: 20209563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
